The Hickory Algorithm
What poor sleep actually does to your brain and heart.
Sleep Is Not a Luxury.
It’s a Longevity Drug.
What poor sleep actually does to your brain and heart — and why perimenopause makes it harder and higher-stakes at the same time.
Most women I talk to treat sleep as a deficit they’re perpetually running. Something they’ll catch up on eventually, if the kids get easier, if work slows down, if the night sweats stop. They know they’re not sleeping well. They’ve been not sleeping well for years. They’ve adjusted.
What they often don’t know is that the adjustment carries a cost. Not just in how they feel day to day, but in what’s accumulating in their bodies while the sleep debt piles up: arterial stiffness, elevated inflammatory markers, amyloid proteins building in the brain. The consequences of chronic poor sleep don’t announce themselves in real time. They show up a decade later, in the form of heart disease, dementia, metabolic dysfunction.
Perimenopause is the exact moment when sleep problems most commonly begin in women’s lives, and also the moment when the long-term stakes of those problems are highest. That’s not a coincidence. It’s a convergence worth understanding.
Why Sleep Gets Harder During the Transition
Sleep disruption in perimenopause isn’t just a symptom of hot flashes, though hot flashes contribute significantly. It’s a more fundamental hormonal story.
Estrogen and progesterone both support sleep quality through distinct mechanisms. Estrogen helps regulate body temperature, supports serotonin production, and reduces the time it takes to fall asleep. It decreases nighttime awakenings and increases total sleep time. Progesterone has direct sedative and anxiolytic properties — it acts on the same GABA receptors that benzodiazepines target, and its decline removes a natural calming effect on the nervous system. As both hormones fluctuate and ultimately decline across the menopausal transition, the architecture of sleep changes: it becomes lighter, more fragmented, less restorative.
Rising FSH levels, which begin years before the final menstrual period, are independently associated with difficulty staying asleep. The declining estrogen that follows is associated with difficulty falling asleep as well. A 2024 narrative review covering publications through May 2024 found that sleep disorder prevalence rises from 16–47% during perimenopause to 35–60% after menopause. These are not trivial rates. More than half of women in postmenopause experience clinically meaningful sleep disruption.
Hot flashes deserve special mention here because their relationship to sleep is more complicated than it appears. Research suggests that in many women, the wakefulness comes first — the brain is already aroused — and the hot flash is what they notice and remember. The hot flash isn’t simply waking them up. The hot flash is the thing they’re aware of in an already-disrupted brain state. This distinction matters because it means treating hot flashes alone may not fully restore sleep. The underlying neurological and hormonal environment needs attention too.
Sleep apnea also rises sharply after menopause. Postmenopausal women are two to three times more likely to develop obstructive sleep apnea than premenopausal women. Progesterone has respiratory stimulant properties that help keep the upper airway patent during sleep. Its loss increases airway collapsibility. Women’s sleep apnea also tends to present differently than men’s, with insomnia and fatigue as more common symptoms rather than the loud snoring that prompts evaluation in men. As a result, it goes undiagnosed far more often — and undiagnosed sleep apnea has its own independent cardiovascular consequences.
What Poor Sleep Does to Your Heart
The connection between sleep and cardiovascular disease in midlife women is no longer theoretical. The SWAN study — the Study of Women’s Health Across the Nation — followed 2,964 women over 22 years, assessing sleep up to 16 times across the observation period. It’s one of the longest and most rigorous longitudinal studies of women’s health ever conducted.
The findings, published in Circulation in 2024, were unambiguous. Women who experienced chronic insomnia symptoms over the course of midlife had significantly elevated risk for cardiovascular events later in life. The effect was most pronounced in women who also had chronically short sleep duration. And critically, this relationship was not explained by other cardiovascular risk factors, vasomotor symptoms, mood disorders, or sleep apnea. The insomnia-to-cardiovascular risk link was independent.
One night of sleep deprivation is associated with increased arterial stiffness in otherwise healthy adults. Chronic sleep disruption promotes endothelial dysfunction, elevates inflammatory markers like IL-6 and CRP, raises blood pressure, worsens insulin resistance, and accelerates atherosclerosis. These are not background effects. They are the same physiological pathways that drive heart attack and stroke. (Arteriosclerosis, Thrombosis, and Vascular Biology, 2023; Pan et al., Biomedical Reports, 2023)
A separate 2023 meta-analysis found that individuals sleeping five hours or fewer per night had meaningfully elevated risk of cardiovascular events across multiple populations and age groups. The optimal window, consistent across studies, is seven to nine hours. Below that, cardiovascular risk rises. But above nine hours consistently is also associated with adverse outcomes — an important nuance that points toward sleep quality, not just quantity, as the target.
For women in perimenopause, the cardiovascular risk from sleep disruption compounds the vascular risk from estrogen decline itself. These are not separate problems stacking on each other. They share mechanisms. Poor sleep elevates the same inflammatory cytokines that estrogen normally suppresses. It worsens the insulin resistance and lipid dysfunction that the hormonal transition is already driving. The two processes are mutually reinforcing.
What Poor Sleep Does to Your Brain
The relationship between sleep and Alzheimer’s disease has shifted from observational association to mechanistic explanation in the past decade. We now understand something specific about why sleep protects the brain — and why losing it matters.
The brain has a waste clearance system called the glymphatic system. During sleep, particularly deep slow-wave sleep, cerebrospinal fluid flows through the brain in a way that clears metabolic byproducts, including amyloid-beta and tau proteins. These are the proteins that accumulate in Alzheimer’s disease. The glymphatic system operates predominantly during sleep. It is essentially inactive during waking hours.
A 2025 randomized crossover clinical trial published in Nature Communications provided the first direct human evidence that the glymphatic system clears amyloid-beta and tau from the brain into plasma during sleep. When participants were sleep-deprived for a night, this clearance did not occur. The proteins that would have been cleared overnight instead remained. The researchers described glymphatic enhancement as a potential therapeutic target for preventing Alzheimer’s progression. This is the sleep-dementia link, confirmed in human tissue. (Dagum et al., Nature Communications, 2025)
Chronic sleep deprivation creates a compounding problem. Less clearance leads to more amyloid accumulation. More amyloid accumulation further impairs the glymphatic system’s ability to function. It becomes a self-reinforcing cycle. The brain damage that leads to Alzheimer’s disease begins accumulating silently, often 15–20 years before any clinical symptoms appear. The sleep disruption happening in perimenopause is occurring in the exact window when that accumulation process begins.
A 2023 UK Biobank study of 154,549 postmenopausal women found that earlier age at menopause was independently associated with increased risk of all-cause dementia, Alzheimer’s disease, and vascular dementia, and with reduced grey matter volume and increased white matter hyperintensities on MRI. The mechanism runs through estrogen deprivation and, importantly, through the sleep disruption that estrogen deficiency causes. Sleep is one of the pathways through which hormonal change affects brain aging.
Women develop Alzheimer’s disease at roughly twice the rate of men. This disparity is not fully explained by the fact that women live longer. The hormonal transition itself, and the sleep disruption it drives, appears to be part of the story.
The Hierarchy of What Actually Helps
There is no single intervention that restores sleep in perimenopause. What works depends on what is driving the disruption. The most honest framework is to address contributors in layers.
Address the hormonal environment first
If hot flashes or night sweats are fragmenting sleep, treating vasomotor symptoms is the most direct path to sleep improvement. A 2017 meta-analysis of 42 trials covering over 15,000 women found that menopausal hormone therapy improved subjective sleep quality in women with vasomotor symptoms. The improvement tracked the improvement in VMS. For women whose sleep disruption is driven primarily by hot flashes, the hormone conversation and the sleep conversation are the same conversation.
Micronized progesterone, specifically, has shown more consistent benefit for sleep than synthetic progestins. Its direct action on GABA receptors provides a sedative effect beyond its role in vasomotor symptom management. Some providers use low-dose micronized progesterone as a targeted sleep intervention even in women who don’t need full systemic hormone therapy.
For women who cannot or choose not to use hormone therapy, non-hormonal options for vasomotor symptoms have improved substantially. Fezolinetant (a neurokinin B receptor antagonist) received FDA approval in 2023 specifically for moderate to severe hot flashes and has shown meaningful sleep improvement in clinical trials.
Cognitive behavioral therapy for insomnia
CBT-I is the most evidence-based treatment for insomnia across all populations, and it’s the first-line recommendation from sleep medicine authorities before pharmacologic intervention. It works by directly addressing the thought patterns and behavioral habits that perpetuate insomnia regardless of its origin. In perimenopausal women, it is effective even when hormonal factors are contributing. Multiple systematic reviews have confirmed its benefit in this population.
CBT-I is not simply “sleep hygiene advice.” It includes sleep restriction therapy, stimulus control, and cognitive restructuring. It is delivered in a structured protocol, typically over six to eight sessions, and the effects are durable in a way that medication effects often are not. Many digital CBT-I programs now make it accessible without a clinician referral.
Sleep architecture, not just sleep duration
The glymphatic clearance that protects the brain occurs predominantly during slow-wave, deep sleep. Alcohol disrupts deep sleep architecture even while making it easier to fall asleep initially — a trade that is worse than it looks. Stimulants consumed after midday delay sleep onset and reduce deep sleep. Heavy exercise within three hours of bedtime elevates core temperature and sympathetic tone in ways that delay sleep onset for many people. Consistent sleep and wake times anchor the circadian rhythm, which governs not just when you sleep but the quality and composition of that sleep.
Bedroom temperature matters. The body’s core temperature needs to drop by one to two degrees Fahrenheit to initiate and maintain sleep. For women with vasomotor symptoms, this process is actively disrupted by hot flashes. A cool sleep environment, moisture-wicking bedding, and in some cases bed cooling devices can meaningfully reduce this disruption.
Sleep apnea: the missed diagnosis
If sleep isn’t improving despite addressing hormonal factors and sleep behaviors, consider sleep apnea. It is substantially underdiagnosed in women, and the symptoms in women are often fatigue and insomnia rather than the loud snoring that prompts men to get evaluated. A home sleep study is now widely available and requires only a referral. Untreated sleep apnea independently drives cardiovascular risk, insulin resistance, and cognitive decline. It is worth ruling out.
A practical note: the conversation about sleep often doesn’t happen at annual exams because time is short and there’s a tendency to treat it as a lifestyle issue rather than a clinical one. If you are not sleeping well and it has been going on for months, it is worth bringing it as a primary concern, not an afterthought. What’s happening in your sleep is affecting your cardiovascular system, your brain, and your metabolic health in ways that are measurable and compound over time.
The Bigger Frame
Sleep is the biological process through which your brain clears its waste, your cardiovascular system recovers, your metabolic hormones reset, and your immune system consolidates its defenses. It is not passive. It is active maintenance, happening every night when it works right.
In perimenopause, the hormonal changes that affect so many other systems also compromise sleep, precisely when sleep’s long-term consequences are most significant. The brain accumulates amyloid in the 40s and 50s. The arteries begin stiffening. The inflammatory burden is rising.
Treating sleep disruption in this window is not about comfort. It is about the same thing as addressing cardiovascular risk, muscle mass, and bone density: deciding how you are going to age, while there is still leverage to influence it.
Sources
All clinical information is drawn from peer-reviewed research.
El Khoudary SR, et al. Trajectories of Sleep Over Midlife and Incident Cardiovascular Disease Events in the Study of Women’s Health Across the Nation. Circulation. 2024;149(7):e93-e621. [2,964 women; 22-year follow-up; chronic insomnia independently associated with CVD events.]
Frange C, et al. Sleep Disturbance and Perimenopause: A Narrative Review. Journal of Clinical Medicine. 2025;14(5):1479. [Databases reviewed through May 2024; prevalence 16–47% perimenopause, 35–60% postmenopause.]
Jehan S, et al. Sleep Disorders and Menopause. Journal of Sleep Medicine & Disorders. 2015/PMC 2019. [Hormonal mechanisms; progesterone GABA receptor action; estrogen and sleep architecture.]
Menopause Journal (LWW). Sleep Disturbance Associated with the Menopause. Menopause. 2024;31(8). [FSH and difficulty staying asleep; estradiol and sleep latency; progesterone and NREM/GABA.]
Dagum P, Elbert DL, Giovangrandi L, et al. The Glymphatic System Clears Amyloid Beta and Tau from Brain to Plasma in Humans. Nature Communications. 2025. [Randomized crossover trial, N=39; first direct human confirmation of glymphatic amyloid-beta and tau clearance during sleep.]
PMC. The Sleeping Brain: Harnessing the Power of the Glymphatic System through Lifestyle Choices. 2020. [Glymphatic system mechanics; amyloid accumulation feedback loop; lifestyle interventions.]
eClinicalMedicine (Lancet). Association of Earlier Age at Menopause with Risk of Incident Dementia, Brain Structural Indices and the Potential Mediators. 2023. [154,549-woman UK Biobank cohort; earlier menopause associated with dementia, reduced grey matter, increased white matter hyperintensities.]
Pan Y, et al. The Association Between Sleep Deprivation and the Risk of Cardiovascular Diseases: A Systematic Meta-Analysis. Biomedical Reports. 2023;19(5):78. [≤5-6h sleep duration and CVD risk; sex and age subgroup analysis.]
Li X, et al. Sleep Deprivation Promotes Endothelial Inflammation and Atherogenesis by Reducing Exosomal miR-182-5p. Arteriosclerosis, Thrombosis, and Vascular Biology. 2023;43(6):995–1014.
Kravitz HM, et al. Sleep Trajectories Before and After the Final Menstrual Period in SWAN. Current Sleep Medicine Reports. 2017;3:235–250.
Cintron D, et al. Efficacy of Menopausal Hormone Therapy on Sleep Quality: Systematic Review and Meta-Analysis. Endocrine. 2017 [meta-analysis of 42 trials, N=15,468; MHT improved sleep in women with VMS].
Johns Hopkins Medicine. How Does Menopause Affect My Sleep? [Postmenopausal women 2–3x more likely to develop sleep apnea; underdiagnosis in women.]
Briceno Silva G, et al. Influence of the Onset of Menopause on the Risk of Developing Alzheimer’s Disease. Cureus. 2024;16(9):e69124.
Previous weekly posts by Jennifer Goldby CNM, in the Hickory Algorithm:
 | A guest post by
|